Skip to main content

Table 1 Demographics of patients with Pseudomonas aeruginosa bacteraemia

From: The impact of infectious diseases consultation on the management and outcomes of Pseudomonas aeruginosa bacteraemia in adults: a retrospective cohort study

  All patients
(n = 128)
+IDC
(n = 91)
-IDC
(n = 37)
P Value
Age (years): Median 68 62 66 0.203
IQR 59–78 43–75 47–77
Male: n (%) 69 (53.9) 51 (56.0) 18 (48.6) 0.572
Comorbidities and medical history: n (%)
 Charlson comorbidity index (severe, score ≥ 5) 78 (60.9) 50 (54.9) 28 (75.7) 0.048
 Haematological malignancy 46 (35.9) 35 (38.5) 11 (29.7) 0.465
 Solid organ tumour 28 (21.9) 18 (19.8) 10 (27.0) 0.507
 Diabetes 22 (17.2) 13 (14.3) 9 (24.3) 0.269
 Liver cirrhosis 15 (11.7) 12 (13.2) 3 (8.1) 0.612
 Renal insufficiency 25 (19.5) 20 (22.0) 5 (13.5) 0.396
 Heart failure 9 (7.0) 4 (4.4) 5 (13.5) 0.148
 Immunosuppressed 86 (67.2) 59 (64.8) 27 (73.0) 0.496
Admitting Teams: n (%)     0.455
 Hematology 48 (37.5) 36 (39.6) 12 (32.4)
 General medicine 31 (24.2) 19 (20.9) 12 (32.4)
 Medical oncology 26 (20.3) 18 (19.8) 8 (21.6)
 Renal medicine 5 (3.9) 3 (3.3) 2 (5.4)
 Urology 5 (3.9) 5 (5.5) 0 (0)
 Other a 13 (10.2) 9 (9.9) 4 (10.8)
  1. Abbreviations: IQR interquartile range, +IDC received infectious diseases specialist consultation, −IDC did not receive infectious diseases specialist consultation
  2. a Other group includes General surgery, Gastroenterology, Cardiology, Cardiothoracic, Neurology, Orthopaedics, Radiation Oncology and Vascular teams